Polar Capital’s Neurogene NGNE Stock Holding History

Polar Capital’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,500	Closed	-$704K	–	251
2017 Q2	$704K	Buy	2,500 +500	+25%	+$143K	0.01%	234
2017 Q1	$668K	Buy	2,000 +250	+14%	+$87.8K	0.01%	245
2016 Q4	$578K	Buy	+1,750	New	+$471K	0.01%	250

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Polar Capital's NGNE Position: Q3 2017 in Review

Polar Capital sold out of Neurogene (NGNE) in Q3 2017, closing a stake of 2,500 shares — an estimated $704K sold.

Polar Capital first reported a position in NGNE in Q4 2016 and held it in 3 quarters. The position peaked at $704K in Q2 2017. 43 funds tracked by Wall St. Rank hold NGNE as of Q3 2017.

Polar Capital reported no remaining Neurogene position as of Q3 2017 after selling out during the quarter.
Polar Capital sold 2,500 Neurogene shares in Q3 2017, an estimated $704K.
Polar Capital first reported a position in Neurogene in Q4 2016 and held it in 3 quarters.
Polar Capital's Neurogene position peaked at $704K in Q2 2017.
43 funds tracked by Wall St. Rank held Neurogene as of Q3 2017.

Based on Polar Capital's 13F filing for Q3 2017, filed 14 Nov 2017.